S100A10, a novel biomarker in pancreatic ductal adenocarcinoma
Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-11-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.12356 |
| _version_ | 1819157476560338944 |
|---|---|
| author | Moamen Bydoun Andra Sterea Henry Liptay Andrea Uzans Weei‐Yuarn Huang Gloria J. Rodrigues Ian C.G. Weaver Hong Gu David M. Waisman |
| author_facet | Moamen Bydoun Andra Sterea Henry Liptay Andrea Uzans Weei‐Yuarn Huang Gloria J. Rodrigues Ian C.G. Weaver Hong Gu David M. Waisman |
| author_sort | Moamen Bydoun |
| collection | DOAJ |
| description | Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the plasminogen receptor S100A10 as a novel predictive biomarker and a driver of pancreatic tumor growth and invasion. We demonstrated that S100A10 mRNA and protein are overexpressed in human pancreatic tumors compared to normal ducts and nonductal stroma. S100A10 mRNA and methylation status were predictive of overall survival and recurrence‐free survival across multiple patient cohorts. S100A10 expression was driven by promoter methylation and the oncogene KRAS. S100A10 knockdown reduced surface plasminogen activation, invasiveness, and in vivo growth of pancreatic cancer cell lines. These findings delineate the clinical and functional contribution of S100A10 as a biomarker in pancreatic cancer. |
| first_indexed | 2024-12-22T16:09:22Z |
| format | Article |
| id | doaj.art-869647be7d2744d6af932b6794d0446a |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-12-22T16:09:22Z |
| publishDate | 2018-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-869647be7d2744d6af932b6794d0446a2022-12-21T18:20:31ZengWileyMolecular Oncology1574-78911878-02612018-11-0112111895191610.1002/1878-0261.12356S100A10, a novel biomarker in pancreatic ductal adenocarcinomaMoamen Bydoun0Andra Sterea1Henry Liptay2Andrea Uzans3Weei‐Yuarn Huang4Gloria J. Rodrigues5Ian C.G. Weaver6Hong Gu7David M. Waisman8Department of Pathology Dalhousie University Halifax Nova Scotia CanadaDepartment of Physiology and Biophysics Dalhousie University Halifax Nova Scotia CanadaDepartment of Biology Dalhousie University Halifax Nova Scotia CanadaDalhousie Medical School Dalhousie University Halifax Nova Scotia CanadaDepartment of Pathology Dalhousie University Halifax Nova Scotia CanadaDepartment of Psychology and Neuroscience Dalhousie University Halifax Nova Scotia CanadaDepartment of Pathology Dalhousie University Halifax Nova Scotia CanadaDepartment of Mathematics and Statistics Dalhousie University Halifax Nova Scotia CanadaDepartment of Pathology Dalhousie University Halifax Nova Scotia CanadaPancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the plasminogen receptor S100A10 as a novel predictive biomarker and a driver of pancreatic tumor growth and invasion. We demonstrated that S100A10 mRNA and protein are overexpressed in human pancreatic tumors compared to normal ducts and nonductal stroma. S100A10 mRNA and methylation status were predictive of overall survival and recurrence‐free survival across multiple patient cohorts. S100A10 expression was driven by promoter methylation and the oncogene KRAS. S100A10 knockdown reduced surface plasminogen activation, invasiveness, and in vivo growth of pancreatic cancer cell lines. These findings delineate the clinical and functional contribution of S100A10 as a biomarker in pancreatic cancer.https://doi.org/10.1002/1878-0261.12356DNA methylationKRASpancreatic ductal adenocarcinomaplasminogenS100A10 |
| spellingShingle | Moamen Bydoun Andra Sterea Henry Liptay Andrea Uzans Weei‐Yuarn Huang Gloria J. Rodrigues Ian C.G. Weaver Hong Gu David M. Waisman S100A10, a novel biomarker in pancreatic ductal adenocarcinoma Molecular Oncology DNA methylation KRAS pancreatic ductal adenocarcinoma plasminogen S100A10 |
| title | S100A10, a novel biomarker in pancreatic ductal adenocarcinoma |
| title_full | S100A10, a novel biomarker in pancreatic ductal adenocarcinoma |
| title_fullStr | S100A10, a novel biomarker in pancreatic ductal adenocarcinoma |
| title_full_unstemmed | S100A10, a novel biomarker in pancreatic ductal adenocarcinoma |
| title_short | S100A10, a novel biomarker in pancreatic ductal adenocarcinoma |
| title_sort | s100a10 a novel biomarker in pancreatic ductal adenocarcinoma |
| topic | DNA methylation KRAS pancreatic ductal adenocarcinoma plasminogen S100A10 |
| url | https://doi.org/10.1002/1878-0261.12356 |
| work_keys_str_mv | AT moamenbydoun s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT andrasterea s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT henryliptay s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT andreauzans s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT weeiyuarnhuang s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT gloriajrodrigues s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT iancgweaver s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT honggu s100a10anovelbiomarkerinpancreaticductaladenocarcinoma AT davidmwaisman s100a10anovelbiomarkerinpancreaticductaladenocarcinoma |